Skip to main content

Table 1 Bacteria identified in the TTM-1 and ANTHARTIC trials with local susceptibility data to ceftriaxone

From: Ceftriaxone to PRevent pneumOnia and inflammaTion aftEr Cardiac arresT (PROTECT): study protocol for a randomized, placebo-controlled trial

Bacteria

TTM-1 triala

ANTHARTIC triala

MMC ceftriaxone susceptibilityb

Gram-positive

 Staphylococcus aureus

22.9%

12%

86%

 Streptococcus pneumoniae

5.5%

7%

99%

 Streptococcus agalactiae

1.5%

3%

Not reported

Gram-negative

 Haemophilus influenzae

9.1%

22%

100%

 Escherichia coli

9.1%

11%

93%

 Klebsiella pneumoniae

5.1%

4%

94%

 Serratia marcescens

5.1%

3%

89%

 Klebsiella oxytoca

3.6%

1%

97%

 Enterobacter cloacae

3.3%

3%

78%

 Pseudomonas aeruginosa

2.5%

3%

Not active

 Enterobacter aerogenes

2.2%

2%

75%

 Proteus mirabilis

2.2%

1%

98%

 Moraxella catarrhalis

1.5%

1%

Not reported

  1. aPercentages do not equal 100 for each study as some organisms (e.g., fungi) were not included above
  2. bMaine Medical Center ceftriaxone antibiogram data through December 2019
  3. MMC Maine Medical Center, TTM targeted temperature management